Patents by Inventor Gilla Kaplan

Gilla Kaplan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pre-frontal cortex processing disorder speech, gait and limb impairments treatment
    Patent number: 11102953
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: August 31, 2021
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • PRE-FRONTAL CORTEX PROCESSING DISORDER SPEECH, GAIT AND LIMB IMPAIRMENTS TREATMENT
    Publication number: 20210084863
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.
    Type: Application
    Filed: October 13, 2020
    Publication date: March 25, 2021
    Applicant: Gilrose Pharmaceuticals, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Pre-frontal cortex processing disorder speech gait and limb impairments treatment
    Patent number: 10834891
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: November 17, 2020
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • PRE-FRONTAL CORTEX PROCESSING DISORDER SPEECH GAIT AND LIMB IMPAIRMENTS TREATMENT
    Publication number: 20190320611
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.
    Type: Application
    Filed: June 20, 2019
    Publication date: October 24, 2019
    Applicant: Gilrose Pharmaceuticals, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Pre-frontal cortex processing disorder speech, gait and limb impairments treatment
    Patent number: 10420318
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: September 24, 2019
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • PRE-FRONTAL CORTEX PROCESSING DISORDER SPEECH, GAIT AND LIMB IMPAIRMENTS TREATMENT
    Publication number: 20180352780
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.
    Type: Application
    Filed: August 14, 2018
    Publication date: December 13, 2018
    Applicant: Gilrose Pharmaceuticals, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Pre-frontal cortex processing disorder speech, gait and limb impairments treatment
    Patent number: 10085414
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: October 2, 2018
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • PRE-FRONTAL CORTEX PROCESSING DISORDER SPEECH, GAIT AND LIMB IMPAIRMENTS TREATMENT
    Publication number: 20170251628
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.
    Type: Application
    Filed: May 16, 2017
    Publication date: September 7, 2017
    Applicant: Gilrose Pharmaceuticals, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Pre-frontal cortex processing disorder gait and limb impairments treatment
    Patent number: 9682073
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: June 20, 2017
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Treatment for cerebral palsy gait impairment
    Patent number: 9408838
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment and a speech impairment secondary to a non degenerative disease or disorder acquired in utero, at birth or in infancy, but later manifested.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: August 9, 2016
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • PRE-FRONTAL CORTEX PROCESSING DISORDER GAIT AND LIMB IMPAIRMENTS TREATMENT
    Publication number: 20160199366
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.
    Type: Application
    Filed: March 21, 2016
    Publication date: July 14, 2016
    Applicant: Gilrose Pharmaceuticals, LLC
    Inventors: BRUCE ROSEMAN, Gilla Kaplan
  • Pharmaceutical intervention for treating an apraxia of speech in children
    Patent number: 9375421
    Abstract: A pharmaceutical intervention and therapeutic method for treating an apraxia of speech in children. The child can also be diagnosed with gait abnormalities or impairment autism, mental retardation and dyslexia. If the child demonstrates at least an 18 to 24 month development stage of either verbal development or non-verbal development, a therapeutic dose of a dopamine agonistic, particularly a nonlinear lower alkyl phenidate or dextro-threo-methylphenidate is administered to the child.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: June 28, 2016
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Treatment for cerebral palsy gait impairment
    Patent number: 9333198
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment secondary to cerebral palsy, or a gait impairment resultant side effect from anti-cancer and anti-seizure drugs. The administered methylphenidate simultaneously treats speech and gait or limb impairments secondary to a disease or disorder.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: May 10, 2016
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • PHARMACEUTICAL INTERVENTION AND METHOD FOR TREATING AN APRAXIA OF SPEECH IN CHILDREN
    Publication number: 20160113916
    Abstract: A pharmaceutical intervention and therapeutic method for treating an apraxia of speech in children. The child can also be diagnosed with gait abnormalities or impairment autism, mental retardation and dyslexia. If the child demonstrates at least an 18 to 24 month development stage of either verbal development or non-verbal development, a therapeutic dose of a dopamine agonistic, particularly a nonlinear lower alkyl phenidate or dextro-threo-methylphenidate is administered to the child.
    Type: Application
    Filed: December 15, 2015
    Publication date: April 28, 2016
    Applicant: Gilrose Pharmaceuticals, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • TREATMENT FOR CEREBRAL PALSY GAIT IMPAIRMENT
    Publication number: 20160101095
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment and a speech impairment secondary to a non degenerative disease or disorder acquired in utero, at birth or in infancy, but later manifested.
    Type: Application
    Filed: December 16, 2015
    Publication date: April 14, 2016
    Applicant: Gilrose Pharmaceuticals, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Treatment for cerebral palsy gait impairment
    Patent number: 9307942
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment secondary to cerebral palsy, or a gait impairment resultant side effect from anti-cancer and anti-seizure drugs. The administered methylphenidate simultaneously treats speech and gait or limb impairments secondary to a disease or disorder.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: April 12, 2016
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • TREATMENT FOR CEREBRAL PALSY GAIT IMPAIRMENT
    Publication number: 20160030411
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment secondary to cerebral palsy, or a gait impairment resultant side effect from anti-cancer and anti-seizure drugs. The administered methylphenidate simultaneously treats speech and gait or limb impairments secondary to a disease or disorder.
    Type: Application
    Filed: October 13, 2015
    Publication date: February 4, 2016
    Applicant: Gilrose Pharmaceuticals, LLC
    Inventors: Bruce ROSEMAN, Gilla KAPLAN
  • Pharmaceutical intervention and method for treating an apraxia of speech in children
    Patent number: 9220712
    Abstract: A pharmaceutical intervention and therapeutic method for treating an apraxia of speech in children. The child can also be diagnosed with gait abnormalities or impairment autism, mental retardation and dyslexia. If the child demonstrates at least an 18 to 24 month development stage of either verbal development or non-verbal development, a therapeutic dose of a dopamine agonistic, particularly a nonlinear lower alkyl phenidate or dextro-threo-methylphenidate is administered to the child.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: December 29, 2015
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • TREATMENT FOR CEREBRAL PALSY GAIT IMPAIRMENT
    Publication number: 20150320734
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment secondary to cerebral palsy, or a gait impairment resultant side effect from anti-cancer and anti-seizure drugs. The administered methylphenidate simultaneously treats speech and gait or limb impairments secondary to a disease or disorder.
    Type: Application
    Filed: July 8, 2015
    Publication date: November 12, 2015
    Applicant: Gilrose Pharmaceuticals, LLC
    Inventors: BRUCE ROSEMAN, Gilla Kaplan
  • Treatment of cerebral palsy impaired speech in children
    Patent number: 9161718
    Abstract: Cerebral palsy impaired speech in children and adolescents are effectively treated by administration of a psychostimulant. Low doses of the psychostimulant significantly increases the percentage of correctly pronounced intelligible syllables or words and the ability to more intelligibly communicate. The improvement in speech persists after cessation of or prior to continued psychostimulant treatment.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: October 20, 2015
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan